Welcome to our dedicated page for Inmune Bio SEC filings (Ticker: INMB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
INmune Bio Inc.'s SEC filings document the disclosure record of a Nasdaq-listed Nevada biotechnology company developing innate-immune therapies. Its filings identify common stock traded under INMB and cover material-event reports, Regulation FD presentations, shareholder letters, clinical and regulatory updates, operating and financial results, and capital-structure disclosures.
Recent 8-K filings include disclosures tied to product-platform communications and a material definitive agreement involving INmune Bio International and Anthony Nolan for the CORDStrom platform. Proxy materials cover shareholder voting and governance matters, while the company’s formal disclosures frame recurring risks and development-stage issues associated with biotechnology research, regulatory pathways, collaborations and financing.
Inmune Bio's Schedule 13G/A shows Praetorian-related entities holding disclosed positions in the company's common stock. Praetorian Capital Fund LLC directly beneficially owns 771,200 shares—comprised of 180,800 shares issuable upon warrants and 590,400 shares underlying call options exercisable within 60 days—representing approximately 2.9% of the class based on 26,585,258 shares outstanding. Mongolia (Barbados) Corp. directly owns 150,000 shares underlying call options (about 0.6%), and Harris Kupperman may be deemed to beneficially own a combined 921,200 shares (about 3.4%).
The filing identifies the reporting persons' roles (investment manager, manager, controlling person) and disclaims beneficial ownership beyond direct holdings. It specifies that reported positions include instruments exercisable within 60 days and includes a certification that the securities were not acquired to change or influence control of the issuer.
INmune Bio (NASDAQ:INMB) filed an 8-K announcing it will host a conference call on June 30, 2025 at 8:00 a.m. ET to present top-line data from its Phase 2 MINDFuL trial in early Alzheimer’s disease.
The filing:
- Attaches the related press release as Exhibit 99.1
- Provides no efficacy or safety figures; full results will be disclosed during the call
- Contains no changes to financial statements or guidance
The scheduling of a data read-out signals analysis completion and sets a near-term catalyst for shareholders, but the document itself does not alter the company’s financial position.